Sign in

CIK 0001798749

  • Emerging growth company

Jade Biosciences, Inc.

Sign in to watch
Ticker
JBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831377888
Phone
+1 781-312-3013
Business address
221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
Former names
Aerovate Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 84 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-06-25 Eisner Mark Director Grant or award · Stock Option (Right to Buy) +47,675 47,675
2026-06-09 CAIN CHRISTOPHER W. Director Grant or award · Stock Option (Right to Buy) +34,843 34,843
2026-06-09 DOBMEIER ERIC Director Grant or award · Stock Option (Right to Buy) +34,843 34,843
2026-06-09 Klein Lawrence Otto Director Grant or award · Stock Option (Right to Buy) +34,843 34,843
2026-06-09 Lavelle Erin Director Grant or award · Stock Option (Right to Buy) +34,843 34,843
2026-06-09 Fairmount Funds Management LLC Director Grant or award · Stock Option (Right to Buy) +34,843 34,843
2026-02-12 Dahms Bradford D. Chief Financial Officer Grant or award +37,813 37,813
2026-02-12 Dahms Bradford D. Chief Financial Officer Grant or award · Stock Option (Right to Buy) +226,875 226,875
2026-02-12 Balta Elizabeth See Remarks Grant or award +28,125 28,125
2026-02-12 Balta Elizabeth See Remarks Grant or award · Stock Option (Right to Buy) +168,750 168,750
2026-02-12 Frohlich Tom Chief Executive Officer Grant or award +78,750 86,331
2026-02-12 Frohlich Tom Chief Executive Officer Grant or award · Stock Option (Right to Buy) +472,500 472,500
2026-02-12 King Andrew James See Remarks Grant or award +41,250 386,113
2026-02-12 King Andrew James See Remarks Grant or award · Stock Option (Right to Buy) +247,500 247,500
2025-10-06 Fairmount Funds Management LLC Director Grant or award +1,333,126 $9.14 $12.2M 1,897,677
2025-10-06 Fairmount Funds Management LLC Director Grant or award · Pre-Funded Warrant (Right to Buy) +855,047 $9.14 $7.8M 855,047
2025-07-14 Dahms Bradford D. Chief Financial Officer Grant or award · Stock Option (Right to Buy) +526,000 526,000
2025-05-16 Frohlich Tom Chief Executive Officer Purchase +6,000 $7.40 $44K 6,000
2025-04-29 Fairmount Funds Management LLC Director Grant or award · Stock Option (Right to Buy) +23,017 23,017
2025-04-29 Lavelle Erin Director Grant or award · Stock Option (Right to Buy) +23,017 23,017

Page 1 of 16 · 315 trades